Search Results - Boards

Play Episode

5min

Proactive - Interviews for investors

The Vaccine Group teams up with animal health giant Syva on breakthrough pig vaccine

Jeremy Salt, CEO of The Vaccine Group (TVG), a Frontier IP Group PLC portfolio company, talked with Proactive's Stephen Gunnion about the company’s collaboration with global animal health firm Syva. Salt explained that the partnership focuses on developing a vaccine for Streptococcus suis, a major disease in pigs that also contributes significantly to the use of antibiotics in livestock farming. “One of the key aspects of this collaboration with them is that they have a significant gap in their portfolio of products for pigs,” Salt noted. He emphasised that Streptococcus suis is prevalent in around 60% of European countries and impacts pig farming worldwide, with antimicrobial resistance (AMR) being a critical concern. The zoonotic nature of the disease, particularly in Southeast Asia, adds another layer of urgency to develop effective solutions. Salt highlighted that TVG’s vaccine platform provides broader protection across multiple strains, making it potentially globally applicable. The vaccine can be administered to young piglets, which is strategically important and is also expected to be more cost-effective than conventional options. He also discussed the role of UK government support, with Innovate UK and DEFRA grants contributing around £1 million in funding. The company is also progressing with 12 vaccine candidates, including developments in poultry and biotherapeutics delivery using monoclonal antibodies. For more updates, visit Proactive's YouTube channel. Don't forget to like the video, subscribe to the channel, and turn on notifications for future content. #AnimalHealth #Vaccines #SwineIndustry #AntimicrobialResistance #BiotechNews #TVG #FrontierIP #ProactiveInvestors #PigHealth #ZoonoticDiseases #LivestockFarming #VeterinaryInnovation #MonoclonalAntibodies #PoultryVaccines #Biotherapeutics

Proactive - Interviews for investors

Ilika CEO Graeme Purdy on new scale-up milestone for Goliath battery

Ilika PLC CEO Graeme Purdy talked with Proactive's Stephen Gunnion about the company’s latest progress in scaling up its Goliath solid-state battery technology. The discussion focused on improved results from Ilika’s collaboration with the UK Battery Industrialisation Centre (UKBIC). Purdy said: “We’re seeing an improved yield out of the industrialised process,” adding that this reduces waste and lowers costs. More notably, the batteries produced via UKBIC’s process outperform those created on Ilika’s pilot line, showing stronger power density and faster charge-discharge capabilities. Purdy confirmed the project’s shift from process to performance, marking the completion of a £2.7 million grant-supported programme funded by the Advanced Propulsion Centre. He also referenced recent government pledges of £2 billion to back automotive electrification, suggesting that future grant funding could help support Ilika’s product roadmap without shareholder dilution. Looking ahead, Ilika plans to release its P1.5 prototypes—10Ah cells—later this summer. Once enough testing data is gathered, the batteries will be shared with OEMs and Tier 1 suppliers enrolled in its evaluation programme. Purdy also teased the release of 50Ah P2 prototypes by year-end, built on insights gained from the Faraday Battery Challenge. Visit Proactive’s YouTube channel for more videos, and don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #IlikaPLC #GoliathBattery #SolidStateBatteries #EVTechnology #BatteryInnovation #UKBIC #AutomotiveElectrification #AdvancedPropulsion #BatteryManufacturing #GraemePurdy

Proactive - Interviews for investors

IXICO CEO on H1 trading update and revenue drivers in Alzheimer’s trials

IXICO plc CEO Bram Goorden talked with Proactive's Stephen Gunnion about the company’s strategy for innovation, leadership, and growth in the neurodegenerative disease space. Goorden outlined how IXICO’s precision medicine platform, TTNx, uses AI to analyse imaging data for pharmaceutical and biotech companies developing new drugs, particularly in Alzheimer’s, Parkinson’s, and Huntington’s diseases. The CEO emphasised that the company's focus remains on expanding its portfolio, enhancing analytics within existing programs, and tapping into emerging opportunities like blood-based biomarkers. “You may know that IXICO is an absolute leader in especially rare diseases, Huntington's disease and so on, but we've really seen that expansion of portfolio,” Goorden said. He also discussed the company’s strategic pillars: Innovate, Lead, and Scale. This includes integrating new algorithms, raising the company’s voice in the global precision medicine market, and strengthening its US operations to support further growth. Goorden noted that IXICO is seeing increased engagement from partners seeking FDA approvals who rely on gold-standard imaging for validation. He also mentioned the company’s recent hires and commitment to driving more partnerships throughout 2025. Visit Proactive’s YouTube channel for more exclusive interviews and insights. Don’t forget to like this video, subscribe to our channel, and turn on notifications for future updates. #IXICO #BramGoorden #PrecisionMedicine #NeurodegenerativeDiseases #AlzheimersResearch #ParkinsonsDisease #DrugDevelopment #AIinHealthcare #Biomarkers #ClinicalTrials #HealthcareInnovation #FDAapproval

Proactive - Interviews for investors

Pantheon Resources provides update on MEGREZ-1 flow testing results

Pantheon Resources Chairman David Hobbs and CEO Max Easley joined Steve Darling from Proactive to share preliminary flow test results from the Megrez-1 well in Alaska. The well is part of a six-interval testing program, and the first interval tested, the Topset 1 (TS1) reservoir, was fracture stimulated across 290 feet between 7,165 and 7,453 feet measured depth (MD). The well produced sustained strong liquid rates for 12 days, exceeding 1,000 barrels per day by the end of the flow-back period. However, no appreciable hydrocarbons were recovered during this initial test. Despite this, Easley noted the data reveals the TS1 reservoir is oil bearing but likely located within a transition zone that contains limited to no mobile oil or gas. Importantly, the technical data gathered from this interval has boosted the company's confidence in the five remaining, shallower intervals still to be tested. These higher zones are believed to hold greater potential for mobile hydrocarbons and increased productivity. TS1 will now be abandoned, and preparations are underway to begin testing the Lower Prince Creek interval. High-pressure pumping equipment is currently being mobilized to the Megrez pad. While the initial result may seem underwhelming at first glance, Pantheon emphasized that it strengthens their geological model and supports the likelihood of commercial success in the intervals yet to be tested. #proactiveinvestors #pantheonresourcesplc #mining #lse #panr #pthrf #OilAndGas #MEGREZ1 #FlowTesting #EnergyExploration #Hydrocarbons #AlaskaOil #OilDrilling #ResourceDevelopment #OilfieldUpdate

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Board Search Results

Board Search Results

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Board Search Results

Board Search Results

Go Ad-Free